explore -WSS

explore

author：focus 2025-09-02 05:48:07 - browse：27292

Are there still too many biotech companies? How do you know when you’re in a bubble? And is there a wrong way to pronounce “TIGIT”?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Josh Schimmer and Eric Schmidt, two longtime analysts teaming up at Cantor Fitzgerald, join us for a back-to-school conversation as biotech enters the busy back third of 2023. We also discuss the latest news in the life sciences, including some scientific evolution at Biogen, new leadership at Illumina, and the future of CRISPR medicine.

For more on what we cover, here’s the news from Biogen; here’s more on Illumina; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Sports medicine is finally prioritizing gender equality
Next article： With competition flaring, obesity drug hits goal in liver disease study

WSS

340B reform proposal comes out of Senate working group

340B reform proposal comes out of Senate working group

PBM reform efforts get punted in Congress

In utero gene editing: an explainer

Readout LOUD: Venture capital, Gilead, and more M&A

Why CTE doesn’t keep Americans from enjoying the Super Bowl

entertainment

explore

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Drug repurposing or repositioning? The language matters

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Medical leaders decry Supreme Court decision on affirmative action

Alabama frozen embryo ruling has major implications for IVF clinics

Drug repurposing or repositioning? The language matters

Community Health Systems hospitals under DOJ investigation

Hollywood unions extend contract negotiations for actors

Bernie brings in new pharma CEOs to talk drug prices

knowledge

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Readout Newsletter: Amgen, Regeneron, BGI Group and more

AstraZeneca stays mum on Medicare drug pricing negotiations

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

hotspot

focus

hotspot

focus